BASEL, Switzerland, Aug 26 (Reuters) - Approval of Actelion Ltd’s Tracleer for use in a fatal lung disease could double sales of its biggest drug, the biotech company’s chief executive told Reuters.
BASEL, Switzerland, Aug 26 (Reuters) - Approval of Actelion Ltd’s Tracleer for use in a fatal lung disease could double sales of its biggest drug, the biotech company’s chief executive told Reuters.
